Trademark Search in Canada

HMI

View On IC.GC.CA

REGISTERED

on 24 Feb 2021

Last Applicant/ Owned by

HOMOLOGY MEDICINES INC.

44 Hartwell AvenueSuite 102Lexington, MA 02421

Serial Number

1821062 filed on 2^th Feb 2017

Registration Number

TMA1094276 registered on 24^th Feb 2021

Registration expiry Date

24^th Feb 2031

Correspondent Address

CPST INTELLECTUAL PROPERTY INC.

130 Queens Quay EastEast Tower, Suite 809Toronto,

ONTARIO

M5A0P6

HMI

Trademark usage description

pharmaceutical preparations and compositions for the treatment of human genetic disorders; pharmaceutical preparations and compositions for the treatm Read More

Classification Information

Class [005]
Pharmaceutical preparations and compositions for the treatment of human genetic disorders; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations and compositions for regulating the immune system; pharmaceutical preparations and compositions for suppressing tumours; pharmaceutical preparations and compositions for the prevention of osteoporosis; pharmaceutical preparations and compositions for the treatment of autoimmune diseases; pharmaceutical preparations and compositions for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations and compositions for the treatment of blood disorders; pharmaceutical preparations and compositions for the treatment of bone diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations and compositions for the treatment of cardiovascular diseases; pharmaceutical preparations and compositions for the treatment of carpal tunnel syndrome; pharmaceutical preparations and compositions for the treatment of chronic pain; pharmaceutical preparations and compositions for the treatment of cranial or facial nerve disorders; pharmaceutical preparations and compositions for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis ("ALS"), spinal muscular atrophy ("SMA") and multiple sclerosis; pharmaceutical preparations and compositions for the treatment of dental and oral diseases; pharmaceutical preparations and compositions for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations and compositions for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations and compositions for the treatment of drug and alcohol abuse; pharmaceutical preparations and compositions for the treatment of erectile dysfunction; pharmaceutical preparations and compositions for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations and compositions for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations and compositions for the treatment of glaucoma; pharmaceutical preparations and compositions for the treatment of headaches; pharmaceutical preparations and compositions for the treatment of heart rhythm disorders; pharmaceutical preparations and compositions for the treatment of hypercholesteremia; pharmaceutical preparations and compositions for the treatment of hypercholesterolemia; pharmaceutical preparations and compositions for the treatment of hyperlipidemia; pharmaceutical preparations and compositions for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations and compositions for the treatment of infectious diseases, namely respiratory infections, eye infections; pharmaceutical preparations and compositions for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations and compositions for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations and compositions for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations and compositions for the treatment of metabolic diseases and disorders, namely rare or orphan metabolic diseases of the liver, namely phenylketonuria, intrahepatic cholestasis, glycogen storage disease, hemophilia type A, hemophilia type B, alpha-1 antitrypsin deficiency, citrullinemia, tyrosinemia, Wilson disease, Wolman disease, Crigler-Najjar syndrome; pharmaceutical preparations and compositions for the treatment of myalgia and neuralgia; pharmaceutical preparations and compositions for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations and compositions for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations and compositions for the treatment of neuromuscular diseases and disorders; pharmaceutical preparations and compositions for the treatment of oncological diseases and disorders; pharmaceutical preparations and compositions for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations and compositions for the treatment of physical and psychological addictions, namely, gambling addiction, eating disorders and addictions, nicotine addiction, Internet addiction, drug addiction; pharmaceutical preparations and compositions for the treatment of psychiatric and other brain diseases and disorders, namely, anxiety, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; pharmaceutical preparations and compositions for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia; pharmaceutical preparations and compositions for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations and compositions for the treatment of skin irritations, namely bee stings, sunburn, rashes, sores, corns, calluses, and acne; pharmaceutical preparations and compositions for the treatment of the diseases, disorders and infections of the central nervous system, namely central nervous system infections, central nervous system movement disorders, Friedreich's ataxia, Rett syndrome, Huntington's disease, lysosomal storage diseases with central nervous system manifestations, metachromatic leukodystrophy, mucopolysaccharidoses, Hunter syndrome, neuromuscular disorders, spinal muscular atrophy, spinal cord injury, Parkinson's disease, Alzheimer's disease, ocular disorders, ocular motility disorders, encephalitis, motility disorders; pharmaceutical preparations and compositions for the treatment of viral diseases, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations and compositions for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases; pharmaceutical preparations and compositions for use in oncology; pharmaceutical products and compositions for treating respiratory diseases; pharmaceutical preparations and compositions for the treatment of disorders of the peripheral nervous system; pharmaceutical preparations and compositions for the treatment of disorders of hematopoietic stem cells; pharmaceutical preparations and compositions for the treatment of disorders of CD34+ cells; pharmaceutical preparations and compositions for the treatment of disorders of musculoskeletal system, namely rare or orphan diseases of the musculoskeletal or neuromuscular structures namely motor neuron disease, monomelic amyotrophy, O'Sullivan-McLeod Syndrome, amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscular atrophy, spinal muscular atrophy, muscular channelopathy, myotonic syndrome, myotonic dystrophy, myotubular myopathy, skeletal muscle disease, Duchenne muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, congenital muscular dystrophy; pharmaceutical preparations and compositions for the treatment of disorders of neuromuscular system; pharmaceutical preparations and compositions for the treatment of letabolic disorders; pharmaceutical preparations and compositions for the treatment of liver disorders; pharmaceutical preparations and compositions for the treatment of lung diseases; pharmaceutical preparations and compositions for the treatment of Cystic fibrosis; pharmaceutical preparations and compositions for the treatment of Phenylketonuria; pharmaceutical preparations and compositions for the treatment of Sickle cell disease; pharmaceutical preparations and compositions for the treatment of Beta-thalassemia; pharmaceutical preparations and compositions for the treatment of Duchenne Muscular Dystrophy ("DMD"); pharmaceutical preparations and compositions for the treatment of Friedreich's ataxia; pharmaceutical preparations and compositions for the treatment of metachromatic leukodystrophy; pharmaceutical preparations and compositions for the treatment of mucopolysaccharidoses; pharmaceutical preparations and compositions for the treatment of Hunter syndrome; pharmaceutical preparations and compositions for the treatment of Gaucher disease; pharmaceutical preparations and compositions for the treatment of Pompe disease; pharmaceutical preparations and compositions for the treatment of Fabry disease

Classification kind code

Class [042]
Pharmaceutical research and development services

Classification kind code

Mark Details

Serial Number

1821062

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 42 on 27^th Mar 2019	Advertised
Submitted for opposition 26 on 7^th Mar 2019	Approved
Submitted for opposition 27 on 16^th Jan 2019	Approval Notice Sent
Submitted for opposition 15 on 6^th Dec 2018	Correspondence Created
Submitted for opposition 12 on 14^th May 2018	Extension of Time
Submitted for opposition 22 on 20^th Nov 2017	Search Recorded
Submitted for opposition 20 on 20^th Nov 2017	Examiner's First Report
Submitted for opposition 31 on 7^th Feb 2017	Formalized
Submitted for opposition 1 on 3^rd Feb 2017	Created
Submitted for opposition 30 on 2^th Feb 2017	Filed

HMI

Classification Information

Classification kind code

Class [042]Pharmaceutical research and development services

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [042]
Pharmaceutical research and development services